PDF(Pubmed)
Abstract：
Eslicarbazepine acetate, a third-generation antiepileptic drug (AED), has shown improved clinical response and safety in comparison to older generation AEDs for patients with partial-onset seizures. It is currently not known whether eslicarbazepine acetate is safe to use in patients with the acute hepatic porphyrias (AHPs) since a few first-generation AEDs, such as phenobarbital and carbamazepine, are known porphyrogenic agents. In this study, we used a recently published in vitro fluorescence-based screening assay to screen for porphyrogenicity in various agents. The assay confirmed that among the tested compounds used, allyl isopropyl acetamide, carbamazepine, eslicarbazepine acetate, and phenobarbital were porphyrogenic. Thus, eslicarbazepine acetate should be avoided if possible in patients with the AHPs, but if initiated, patients should be closely monitored and the drug should be discontinued if a porphyric exacerbation occurs.
摘要：
醋酸依西卡西平，第三代抗癫痫药（AED），对于部分发作性癫痫患者，与老一代AED相比，已显示出改善的临床反应和安全性。目前尚不清楚醋酸埃司卡西平是否安全用于急性肝卟啉病（AHP）患者，因为一些第一代AED，如苯巴比妥和卡马西平，是已知的卟啉剂。在这项研究中,我们使用最近发表的基于体外荧光的筛选试验来筛选各种药物中的卟啉性.该测定证实，在使用的测试化合物中，烯丙基异丙基乙酰胺，卡马西平,醋酸艾司利卡西平，苯巴比妥和卟啉症。因此，如果可能的话，AHP患者应避免使用醋酸艾司利卡西平，但如果发起,应密切监测患者,如果出现卟啉恶化,应停用药物.
